Compare Trip.com Group Ltd (TCOM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Trip.com Group Ltd trades at $39.37 (market cap $24.60B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Trip.com Group Ltd is far larger — about 5× Travere Therapeutics Inc. Common Stock's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trip.com Group Ltd for 80 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TCOM | TVTX | |
|---|---|---|
Market Cap | $24.60B | $4.88B |
Volume | 1,981,955 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $67.52 |
52-Week Low | $37.96 | $26.79 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $16.75B | $5.01B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCOM trades at $38.88, up 0.31% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 7.48, net income margin of 36.9%, and robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Recent Q2 2026 earnings beat expectations at $1.07 per share, though Q1 and Q4 2025 missed. Cash flow remains positive with $7.11B net cash flow in 2024, and the balance sheet is healthy with total assets of $242.58B and debt-to-asset ratio improving to 16.37%.
The outlook is mixed: analyst consensus is bullish with a $56.64 price target and 70.45% buy ratings, but regulatory risks and recent antitrust fines pose challenges. Earnings growth and international expansion are key catalysts, yet competition and market volatility require caution. The stock presents value given low valuations, but investors must weigh regulatory headwinds against fundamental strength.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
